@Fire Bull - Well balanced article by Clause Walker - thanks for posting. As long as growth in overseas markets eventuates, this will be a good hold. Clearly, the company has a high cost structure that comes with ensuring integration overseas goes smoothly. However, if overseas growth does not really eventuate in 2019, we could see some painful dilution. Realistically, I suspect management team has 9 months to really deliver on implementation and commensurate revenue generation.
Ann: MedAdvisor FY18 Annual Report & Appendix 4E, page-14
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MDR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
30.0¢ |
Change
0.010(3.45%) |
Mkt cap ! $215.0M | |||
| Open | High | Low | Value | Volume |
| 29.0¢ | 30.0¢ | 27.5¢ | $254.8K | 889.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 39326 | 30.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.5¢ | 2917 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| MDR (ASX) Chart |
